ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

UT Board Announces Support for MD Anderson Tenure System

October 10, 2014

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

December 27, 2013

In Brief: NCI Rushing To Complete Development Of Program Grants System By June 30

May 17, 1974

NCI Is Convinced It Has Isolated Human Cancer Virus

February 14, 1975

FDA Pettiness Holds Up Trials with Promising Anticancer Drugs

November 14, 1975

NIH “RFA Game” Defeats Purpose Of OAM, Advisor Says

September 30, 1994